AZArash Zarrine-Afsar

Arash Zarrine-Afsar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Arash Zarrine-Afsar has a total of 140 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Assessing the Limit of Tumor Infiltration Detection Using Averaged Mass Spectra from a Handheld Picosecond Infrared Laser Mass Spectrometry Probe: A Proof-of-Principle Study

    by Laurentiu G. Dabija, Michael Woolman, Mark Zaidi, Megan Wu, Manjusha Muralidharan, Ziba Jaberansari, Brad G. Wouters, Sunit Das, Howard J. Ginsberg, Deepak Dinakaran, et al.

    Utilizing picosecond infrared laser mass spectrometry (PIRL-MS), we set out to determine the limit of tumor infiltration detection offered by this ambient ion source. Using murine models of brain cancer subjected to handheld PIRL-MS, as well as spatially resolved PIRL-MS imaging and various tissue models, we estimated the limit of tumor infiltration detection to be approximately 15% using physically combined glioblastoma tissue sections and approximately 4% using computational pixel mixing of orthotopic medulloblastoma imaging data. These estimates are broadly consistent in magnitude with independent iKnife-REIMS studies that employed different sampling methods and experimental models. At these detection limits, PIRL-MS predicted positive margins with a sensitivity of 84.21% and a specificity of 86.43%. This observation is based on the analysis of n = 38 orthotopic glioblastoma murine tissue sections bearing various tumor ranges and utilized n = 178 classifiable mass spectral data points. As a proof-of-principle study, these estimates derive from a limited number of biological replicates, including n = 3 subcutaneous xenografts used to construct the tissue model, n = 5 orthotopic animals for validation, and n = 2 tumors underlying the imaging-based estimate and, therefore, should be regarded as preliminary rather than definitive detection limits. These findings highlight the potential of PIRL-MS as a rapid, label-free intraoperative tool for margin assessment and provide insight into the practical limits of tumor infiltration detection in heterogeneous brain tumors.

  • Open Access

    Picosecond infrared laser mass spectrometry for 10-second identification of lymphoproliferative imposter tumours in patient-derived xenografts

    by Lan-Anna Ye, Darah Vlaminck, Alexa Fiorante, Laurentiu G. Dabija, Francis Talbot, Julia Froment, Alhareth Azaizeh, Likun Hou, Ming Li, Yuhui Wang, et al.

    Patient derived xenografts (PDXs) are widely used in preclinical research. However, lymphoproliferative ‘outgrowths’ at the site of tumour xenoplantation are a common source of failure in the creation of the disease model. In this work, we assessed the performance of 10-second molecular profiling of xenoplanted tissue with picosecond infrared laser mass spectrometry (PIRL-MS) as a new method for rapid identification of lymphoproliferative ‘outgrowths’ in serial passages to streamline the quality control workflow. PIRL-MS can identify ‘imposter’ lymphoproliferative tumours with sensitivity and specificity values of > 99%. This observation is established over n = 258 independent PDX specimens and n = 3,393 ten-second mass spectral data points used for building and validating (blind assessment) a classifier multivariate model to enable discrimination. We first established a classifier model based on principal component analysis coupled with linear discriminant analysis (PCA-LDA) to discriminate between true solid tumour PDXs (of 5 common epithelioid cancer types originating from lung, pancreas, ovarian, colon and head & neck as well as imposter tumours of lymphoproliferative origin. Implementation of the classifier only requires 10 seconds of mass spectral data collection (using a hand-held probe) and less than an additional second for data processing and evaluation against the model towards a classification. In addition, PIRL-MS analysis does not require any tissue preparation before analysis, and from previous research can also be deployed in situ/in vivo to save time. These attributes, coupled with its reported high sensitivity and specificity for identification of imposter lymphoproliferative tumours, position PIRL-MS as a rapid quality control method for fidelity assessment of xenoplanted tissues. These observations motivate follow-on work to reduce the cost and the footprint of the PIRL-MS platform towards lowering the adoption barrier for routine use.

  • Open Access

    A molecular array for 10-second diagnosis of common spinal tumor types with picosecond infrared laser mass spectrometry

    by Alexa Fiorante, Michael Woolman, David G Munoz, Taira Kiyota, Lan Anna Ye, Yasmine Farahmand, Darah Vlaminck, Francis O Talbot, Sunit Das, Sorcha Kellett, et al.

    Background: Improving the surgical outcomes for commonly occurring spinal neoplasms of extradural and intradural extramedullary origins requires precise intraoperative diagnosis provided by highly trained neuropathologists. Methods: Through a retrospective study of n = 319 patient specimens, verified where appropriate by learning curve analysis to be sufficient for statistically significant observations, we aimed to assess the utility of 10-second picosecond infrared laser mass spectrometry (MS; PIRL-MS) for non-subjective diagnosis of major spinal tumor types of metastatic carcinoma, schwannoma, and meningiomas. Results: The sensitivity and specificity values of spinal tumor-type diagnosis (based on n = 182 independent specimens) were (93% ± 1)% and (97% ± 2)%, respectively. This classification utilizes n = 41 cellular lipids including phosphatidylcholines, sphingomyelins, phosphatidylethanolamines, and ceramides whose identities were established using high-resolution tandem MS. Furthermore, the accuracy of diagnosis of a model that contained n = 97 meningioma and n = 106 schwannoma was not drastically influenced by the presence of n = 54 additional intradural extramedullary spinal neoplasms of myxopapillary ependymoma, neurofibroma, paraganglioma, and solitary fibrous tumor types in the differential diagnosis, confirming the generalizability and robustness of the identified molecular array in rendering correct classification even in the presence of data not seen previously by the model. Conclusions: The identified lipids form a “molecular array” for robust diagnosis of meningioma and schwannoma tumors by non-pathologists in a manner similar to genomic, transcriptomic, or methylomic arrays used to diagnose brain cancer types, albeit on a much faster timescale of seconds as opposed to hours.


  • Open Access

    A Workflow for Meaningful Interpretation of Classification Results from Handheld Ambient Mass Spectrometry Analysis Probes

    by Alexa Fiorante, Lan Anna Ye, Alessandra Tata, Taira Kiyota, Michael Woolman, Francis Talbot, Yasamine Farahmand, Darah Vlaminck, Lauren Katz, Andrea Massaro, et al.

    While untargeted analysis of biological tissues with ambient mass spectrometry analysis probes has been widely reported in the literature, there are currently no guidelines to standardize the workflows for the experimental design, creation, and validation of molecular models that are utilized in these methods to perform class predictions. By drawing parallels with hurdles that are faced in the field of food fraud detection with untargeted mass spectrometry, we provide a stepwise workflow for the creation, refinement, evaluation, and assessment of the robustness of molecular models, aimed at meaningful interpretation of mass spectrometry-based tissue classification results. We propose strategies to obtain a sufficient number of samples for the creation of molecular models and discuss the potential overfitting of data, emphasizing both the need for model validation using an independent cohort of test samples, as well as the use of a fully characterized feature-based approach that verifies the biological relevance of the features that are used to avoid false discoveries. We additionally highlight the need to treat molecular models as “dynamic” and “living” entities and to further refine them as new knowledge concerning disease pathways and classifier feature noise becomes apparent in large(r) population studies. Where appropriate, we have provided a discussion of the challenges that we faced in our development of a 10 s cancer classification method using picosecond infrared laser mass spectrometry (PIRL-MS) to facilitate clinical decision-making at the bedside.


  • Open Access

    Lipidomic-Based Approach to 10 s Classification of Major Pediatric Brain Cancer Types with Picosecond Infrared Laser Mass Spectrometry

    by Michael Woolman, Taira Kiyota, Siham A. Belgadi, Naohide Fujita, Alexa Fiorante, Vijay Ramaswamy, Craig Daniels, James T. Rutka, Chris McIntosh, David G. Munoz, et al.

    Picosecond infrared laser mass spectrometry (PIRL-MS) is shown, through a retrospective patient tissue study, to differentiate medulloblastoma cancers from pilocytic astrocytoma and two molecular subtypes of ependymoma (PF-EPN-A, ST-EPN-RELA) using laser-extracted lipids profiled with PIRL-MS in 10 s of sampling and analysis time. The average sensitivity and specificity values for this classification, taking genomic profiling data as standard, were 96.41 and 99.54%, and this classification used many molecular features resolvable in 10 s PIRL-MS spectra. Data analysis and liquid chromatography coupled with tandem high-resolution mass spectrometry (LC-MS/MS) further allowed us to reduce the molecular feature list to only 18 metabolic lipid markers most strongly involved in this classification. The identified 'metabolite array' was comprised of a variety of phosphatidic and fatty acids, ceramides, and phosphatidylcholine/ethanolamine and could mediate the above-mentioned classification with average sensitivity and specificity values of 94.39 and 98.78%, respectively, at a 95% confidence in prediction probability threshold. Therefore, a rapid and accurate pathology classification of select pediatric brain cancer types from 10 s PIRL-MS analysis using known metabolic biomarkers can now be available to the neurosurgeon. Based on retrospective mining of 'survival' versus 'extent-of-resection' data, we further identified pediatric cancer types that may benefit from actionable 10 s PIRL-MS pathology feedback. In such cases, aggressiveness of the surgical resection can be optimized in a manner that is expected to benefit the patient's overall or progression-free survival. PIRL-MS is a promising tool to drive such personalized decision-making in the operating theater.


  • Metabolic Lipids in Melanoma Enable Rapid Determination of Actionable BRAF-V600E Mutation with Picosecond Infrared Laser Mass Spectrometry in 10 s

    by Lauren Katz, Taira Kiyota, Michael Woolman, Megan Wu, Layla Pires, Alexa Fiorante, Lan Anna Ye, Wey Leong, Hal K. Berman, Danny Ghazarian, et al.

    Rapid molecular profiling of biological tissues with picosecond infrared laser mass spectrometry (PIRL-MS) has enabled the detection of clinically important histologic types and molecular subtypes of human cancers in as little as 10 s of data collection and analysis time. Utilizing an engineered cell line model of actionable BRAF-V600E mutation, we observed statistically significant differences in 10 s PIRL-MS molecular profiles between BRAF-V600E and BRAF-wt cells. Multivariate statistical analyses revealed a list of mass-to-charge (m/z) values most significantly responsible for the identification of BRAF-V600E mutation status in this engineered cell line that provided a highly controlled testbed for this observation. These metabolites predicted BRAF-V600E expression in human melanoma cell lines with greater than 98% accuracy. Through chromatography and tandem mass spectrometry analysis of cell line extracts, a 30-member "metabolite array" was characterized for determination of BRAF-V600E expression levels in subcutaneous melanoma xenografts with an average sensitivity and specificity of 95.6% with 10 s PIRL-MS analysis. This proof-of-principle work warrants a future large-scale study to identify a metabolite array for 10 s determination of actionable BRAF-V600E mutation in human tissue to guide patient care.


  • Open Access

    Data from Picosecond Infrared Laser Desorption Mass Spectrometry Identifies Medulloblastoma Subgroups on Intrasurgical Timescales

    by Michael Woolman, Claudia M. Kuzan-Fischer, Isabelle Ferry, Taira Kiyota, Betty Luu, Megan Wu, David G. Munoz, Sunit Das, Ahmed Aman, Michael D. Taylor, et al.

    Medulloblastoma (MB) is a pediatric malignant brain tumor composed of four different subgroups (WNT, SHH, Group 3, Group 4), each of which are a unique biological entity with distinct clinico-pathological, molecular, and prognostic characteristics. Although risk stratification of patients with MB based on molecular features may offer personalized therapies, conventional subgroup identification methods take too long and are unable to deliver subgroup information intraoperatively. This limitation prevents subgroup-specific adjustment of the extent or the aggressiveness of the tumor resection by the neurosurgeon. In this study, we investigated the potential of rapid tumor characterization with Picosecond infrared laser desorption mass spectrometry (PIRL-MS) for MB subgroup classification based on small molecule signatures. One hundred and thirteen ex vivo MB tumors from a local tissue bank were subjected to 10- to 15-second PIRL-MS data collection and principal component analysis with linear discriminant analysis (PCA-LDA). The MB subgroup model was established from 72 independent tumors; the remaining 41 de-identified unknown tumors were subjected to multiple, 10-second PIRL-MS samplings and real-time PCA-LDA analysis using the above model. The resultant 124 PIRL-MS spectra from each sampling event, after the application of a 95% PCA-LDA prediction probability threshold, yielded a 98.9% correct classification rate. Post-ablation histopathologic analysis suggested that intratumoral heterogeneity or sample damage prior to PIRL-MS sampling at the site of laser ablation was able to explain failed classifications. Therefore, upon translation, 10-seconds of PIRL-MS sampling is sufficient to allow personalized, subgroup-specific treatment of MB during surgery.Significance:This study demonstrates that laser-extracted lipids allow immediate grading of medulloblastoma tumors into prognostically important subgroups in 10 seconds, providing medulloblastoma pathology in an actionable manner during surgery.

  • Open Access

    Supplementary Data from Picosecond Infrared Laser Desorption Mass Spectrometry Identifies Medulloblastoma Subgroups on Intrasurgical Timescales

    by Michael Woolman, Claudia M. Kuzan-Fischer, Isabelle Ferry, Taira Kiyota, Betty Luu, Megan Wu, David G. Munoz, Sunit Das, Ahmed Aman, Michael D. Taylor, et al.

    Table S1. Sampling events, signal strength and signal persistence of data points used to build the MB subgroup model; Table S2. MB subgroup classifying peak list from PCA-LDA modeling;Table S3. PCA-LDA prediction results of the blind MB subgrouping test; Figure S1. The collection geometry of PIRL-MS setup used in this study; Figure S2. Representative PIRL-MS spectra of MB subgroups; Figure S3. The PCA-LDA model of the 4 MB subgroups upon application of non-subjective data exclusion criteria; Figure S4. The 'low complexity' PCA-LDA model of the 4 MB subgroups utilizing only the top 44 MB subgroup distinguishing m/z values; Figure S5. Hematoxylin and Eosin (H&E) staining of the misclassified and unclassifiable data points; Figure S6. PCA-LDA analysis of the misclassified/unclassifiable data points; Figure S7. Liquid Chromatography (LC) elution profiles of laser plume and tissue extract; Figure S8. The envisioned use scenarios for PIRL-MS technology. We have also per request of the reviewers included information on identification of MB classifying molecules with LC-MS, Intrasample variability in correct subgroup assignment as well as Sample collection and handling prior to access for PIRL-MS sampling

  • Open Access

    Supplementary Data from Picosecond Infrared Laser Desorption Mass Spectrometry Identifies Medulloblastoma Subgroups on Intrasurgical Timescales

    by Michael Woolman, Claudia M. Kuzan-Fischer, Isabelle Ferry, Taira Kiyota, Betty Luu, Megan Wu, David G. Munoz, Sunit Das, Ahmed Aman, Michael D. Taylor, et al.

    Table S1. Sampling events, signal strength and signal persistence of data points used to build the MB subgroup model; Table S2. MB subgroup classifying peak list from PCA-LDA modeling;Table S3. PCA-LDA prediction results of the blind MB subgrouping test; Figure S1. The collection geometry of PIRL-MS setup used in this study; Figure S2. Representative PIRL-MS spectra of MB subgroups; Figure S3. The PCA-LDA model of the 4 MB subgroups upon application of non-subjective data exclusion criteria; Figure S4. The 'low complexity' PCA-LDA model of the 4 MB subgroups utilizing only the top 44 MB subgroup distinguishing m/z values; Figure S5. Hematoxylin and Eosin (H&E) staining of the misclassified and unclassifiable data points; Figure S6. PCA-LDA analysis of the misclassified/unclassifiable data points; Figure S7. Liquid Chromatography (LC) elution profiles of laser plume and tissue extract; Figure S8. The envisioned use scenarios for PIRL-MS technology. We have also per request of the reviewers included information on identification of MB classifying molecules with LC-MS, Intrasample variability in correct subgroup assignment as well as Sample collection and handling prior to access for PIRL-MS sampling

  • Open Access

    Data from Picosecond Infrared Laser Desorption Mass Spectrometry Identifies Medulloblastoma Subgroups on Intrasurgical Timescales

    by Michael Woolman, Claudia M. Kuzan-Fischer, Isabelle Ferry, Taira Kiyota, Betty Luu, Megan Wu, David G. Munoz, Sunit Das, Ahmed Aman, Michael D. Taylor, et al.

    Medulloblastoma (MB) is a pediatric malignant brain tumor composed of four different subgroups (WNT, SHH, Group 3, Group 4), each of which are a unique biological entity with distinct clinico-pathological, molecular, and prognostic characteristics. Although risk stratification of patients with MB based on molecular features may offer personalized therapies, conventional subgroup identification methods take too long and are unable to deliver subgroup information intraoperatively. This limitation prevents subgroup-specific adjustment of the extent or the aggressiveness of the tumor resection by the neurosurgeon. In this study, we investigated the potential of rapid tumor characterization with Picosecond infrared laser desorption mass spectrometry (PIRL-MS) for MB subgroup classification based on small molecule signatures. One hundred and thirteen ex vivo MB tumors from a local tissue bank were subjected to 10- to 15-second PIRL-MS data collection and principal component analysis with linear discriminant analysis (PCA-LDA). The MB subgroup model was established from 72 independent tumors; the remaining 41 de-identified unknown tumors were subjected to multiple, 10-second PIRL-MS samplings and real-time PCA-LDA analysis using the above model. The resultant 124 PIRL-MS spectra from each sampling event, after the application of a 95% PCA-LDA prediction probability threshold, yielded a 98.9% correct classification rate. Post-ablation histopathologic analysis suggested that intratumoral heterogeneity or sample damage prior to PIRL-MS sampling at the site of laser ablation was able to explain failed classifications. Therefore, upon translation, 10-seconds of PIRL-MS sampling is sufficient to allow personalized, subgroup-specific treatment of MB during surgery.Significance:This study demonstrates that laser-extracted lipids allow immediate grading of medulloblastoma tumors into prognostically important subgroups in 10 seconds, providing medulloblastoma pathology in an actionable manner during surgery.